Document/ExhibitDescriptionPagesSize
1: 10-Q Quarterly Report HTML 3.26M
2: EX-10.2 Material Contract HTML 290K
3: EX-10.2(L) Material Contract HTML 80K
4: EX-10.2(M) Material Contract HTML 84K
5: EX-10.2(N) Material Contract HTML 84K
6: EX-10.3 Material Contract HTML 303K
7: EX-10.4 Material Contract HTML 332K
8: EX-10.5 Material Contract HTML 48K
9: EX-10.6 Material Contract HTML 31K
10: EX-10.7 Material Contract HTML 35K
11: EX-10.8 Material Contract HTML 105K
12: EX-31.1 Certification -- §302 - SOA'02 HTML 33K
13: EX-31.2 Certification -- §302 - SOA'02 HTML 33K
14: EX-32.1 Certification -- §906 - SOA'02 HTML 30K
15: EX-32.2 Certification -- §906 - SOA'02 HTML 29K
21: R1 Document And Entity Information Document HTML 81K
22: R2 Consolidated Balance Sheets HTML 167K
23: R3 Consolidated Balance Sheets (Parenthetical) HTML 54K
24: R4 Consolidated Statements Of Income HTML 123K
25: R5 Consolidated Statements of Comprehensive Income HTML 71K
26: R6 Consolidated Statements Of Cash Flows HTML 136K
27: R7 Consolidated Statements Of Changes in Equity HTML 183K
28: R8 Organization HTML 36K
29: R9 Basis Of Presentation and Significant Accounting HTML 53K
Policies
30: R10 Business Acquisitions HTML 33K
31: R11 Business Optimization Initiatives HTML 45K
32: R12 Investments HTML 252K
33: R13 Derivative Financial Instruments HTML 34K
34: R14 Fair Value HTML 285K
35: R15 Income Taxes HTML 35K
36: R16 Medical Claims Payable HTML 131K
37: R17 Debt HTML 45K
38: R18 Commitments And Contingencies HTML 60K
39: R19 Capital Stock HTML 87K
40: R20 Accumulated Other Comprehensive Loss HTML 86K
41: R21 Earnings Per Share HTML 41K
42: R22 Segment Information HTML 145K
43: R23 Leases HTML 62K
44: R24 Goodwill and Other Intangible Assets HTML 82K
45: R25 Basis of Presentation and Significant Accounting HTML 66K
Policies (Policies)
46: R26 Business Optimization Initiatives (Tables) HTML 45K
47: R27 Investments (Tables) HTML 250K
48: R28 Fair Value (Tables) HTML 272K
49: R29 Medical Claims Payable (Tables) HTML 136K
50: R30 Debt (Tables) HTML 33K
51: R31 Capital Stock (Tables) HTML 91K
52: R32 Accumulated Other Comprehensive Loss (Tables) HTML 86K
53: R33 Earnings Per Share (Tables) HTML 39K
54: R34 Segment Information (Tables) HTML 144K
55: R35 Leases (Tables) HTML 64K
56: R36 Goodwill and Other Intangible Assets (Tables) HTML 86K
57: R37 Organization (Details) HTML 33K
58: R38 Basis of Presentation and Signficant Accounting HTML 59K
Policies Basis of Presentation and Significant
Acconting Policies (Details)
59: R39 Business Acquisitions Business Acquisition (Assets HTML 40K
Liabilities Acquired) (Details)
60: R40 Business Optimization Initiatives (Employee HTML 45K
Termination Costs) (Details)
61: R41 Investments (Current And Long-Term Fixed Maturity HTML 88K
Securities, Available-For-Sale) (Details)
62: R42 Investments (Aggregate Fair Value And Gross HTML 81K
Unrealized Loss Of Fixed Maturity Securities In An
Unrealized Loss Position) (Details)
63: R43 Investments (Allowance For Credit Loss HTML 53K
Rollforward) (Details)
64: R44 Investments (Amortized Cost And Fair Value Of HTML 64K
Fixed Maturity Securities, By Contractual
Maturity) (Details)
65: R45 Investments (Current Equity Securities) (Details) HTML 37K
66: R46 Investments (Net Investment Gains/Losses) HTML 59K
(Details)
67: R47 Investments (Narrative) (Details) HTML 51K
68: R48 Derivative Financial Instruments (Financial HTML 36K
Statement Narrative) (Details)
69: R49 Fair Value (Fair Value Measurements By Level For HTML 149K
Assets Measured At Fair Value On A Recurring
Basis) (Details)
70: R50 Fair Value (Reconciliation Of The Beginning And HTML 78K
Ending Balances Of Assets Measured At Fair Value
On A Recurring Basis Using Level III Inputs)
(Details)
71: R51 Fair Value (Carrying And Estimated Fair Values by HTML 63K
Level Of Financial Instruments Not Recorded At
Fair Value On Consolidated Balance Sheet)
(Details)
72: R52 Income Taxes (Narrative) (Details) HTML 38K
73: R53 Medical Claims Payable (Reconciliation Of The HTML 85K
Beginning And Ending Balances For Medical Claims
Payable By Segment) (Details)
74: R54 Medical Claims Payable (Reconciliation Of Net HTML 44K
Incurred Medical Claims To Benefit Expense)
(Details)
75: R55 Medical Claims Payable Medical Claims Payable HTML 52K
(Reconciliation of the Claims Development to the
Claims Liability) (Details)
76: R56 Medical Claims Payable (Narrative) (Details) HTML 48K
77: R57 Debt (Convertible Debenture Details) (Details) HTML 41K
78: R58 Debt (Narrative) (Details) HTML 121K
79: R59 Commitments And Contingencies (Details) HTML 55K
80: R60 Capital Stock (Summary of Cash Dividend Activity) HTML 39K
(Details)
81: R61 Capital Stock (Summary of Share Repurchases) HTML 39K
(Details)
82: R62 Capital Stock (Summary of Stock Option Activity) HTML 66K
(Details)
83: R63 Capital Stock (Nonvested Restricted Stock Activity HTML 53K
Including Restricted Stock Units) (Details)
84: R64 Capital Stock (Fair Values of Options Granted HTML 38K
During The Period Estimated Using Weighted-Average
Assumptions) (Details)
85: R65 Capital Stock (Schedule Of Weighted-Average Fair HTML 33K
Values Determined For The Periods) (Details)
86: R66 Capital Stock (Narrative) (Details) HTML 47K
87: R67 Accumulated Other Comprehensive Loss HTML 114K
(Reconciliation Of The Components Of Accumulated
Other Comprehensive Loss) (Details)
88: R68 Earnings Per Share (Denominator For Basic And HTML 36K
Diluted Earnings Per Share) (Details)
89: R69 Earnings Per Share (Narrative) (Details) HTML 40K
90: R70 Segment Information (Financial Data By Reportable HTML 65K
Segment) (Details)
91: R71 Segment Information Segment Information (Major HTML 59K
Product Revenues for Each Reportable Segment)
(Details)
92: R72 Segment Information (Reconciliation Of Reportable HTML 44K
Segments Operating Revenues To Total Revenues
Reported In The Consolidated Statements Of Income)
(Details)
93: R73 Segment Information (Reconciliation Of Income HTML 50K
Before Income Tax Expense To Reportable Segments
Operating Gain Included In The Consolidated
Statements Of Income) (Details)
94: R74 Segment Information Segment Information HTML 30K
(Narrative) (Details)
95: R75 Leases (Lease and Other Information) (Details) HTML 52K
96: R76 Leases (Reconciliation of Future Lease Payments to HTML 48K
Total Lease Liabilities) (Details)
97: R77 Leases (Narrative) (Details) HTML 39K
98: R78 Goodwill And Other Intangible Assets (Summary Of HTML 50K
The Change In The Carrying Amount Of Goodwill By
Reportable Segment) (Details)
99: R79 Goodwill And Other Intangible Assets (Components HTML 59K
Of Other Intangible Assets) (Details)
100: R80 Goodwill And Other Intangible Assets (Narrative) HTML 46K
(Details)
103: XML IDEA XML File -- Filing Summary XML 186K
101: XML XBRL Instance -- elv-20220630_htm XML 4.73M
102: EXCEL IDEA Workbook of Financial Reports XLSX 213K
17: EX-101.CAL XBRL Calculations -- elv-20220630_cal XML 186K
18: EX-101.DEF XBRL Definitions -- elv-20220630_def XML 888K
19: EX-101.LAB XBRL Labels -- elv-20220630_lab XML 2.09M
20: EX-101.PRE XBRL Presentations -- elv-20220630_pre XML 1.32M
16: EX-101.SCH XBRL Schema -- elv-20220630 XSD 185K
104: JSON XBRL Instance as JSON Data -- MetaLinks 521± 822K
105: ZIP XBRL Zipped Folder -- 0001156039-22-000081-xbrl Zip 861K
Directors who are employed by Elevance Health, Inc. or its subsidiaries do not receive compensation for serving as Directors. However, Directors who are not employees of Elevance Health, Inc. or its subsidiaries
are entitled to receive the following compensation:
CASH COMPENSATION—Retainers
Annual Board Retainer:
• $125,000 for all Directors paid quarterly in advance (in four equal installments of $31,250) on January 1, April 1, July 1 and October 1.
Annual Retainer for Non-Executive Chair of Board:
• $240,000 for the Non-Executive Chair of the Board, if any, paid quarterly in advance (in four equal installments of $60,000) on January 1, April 1, July 1 and October 1.
Annual Retainer for Lead Director:
•$35,000
for the Lead Director of the Board, if any, paid quarterly in advance (in four equal installments of $8,750) on January 1, April 1, July 1 and October 1.
Annual Retainer for Committee Chairs:
• $30,000 for the Chair of the Audit Committee of the Board of Directors paid quarterly in advance (in four equal installments of $7,500) on January 1, April 1, July 1 and October 1.
• $20,000 for the Chair of each other Committee of the Board of Directors paid quarterly in advance (in four equal installments of $5,000) on January 1, April 1, July 1 and October 1.
If a Director is elected to the Board or becomes the Non-Executive Chair
or Lead Director of the Board or a Committee Chair on a date other than the first day of a calendar quarter, the retainers described above will be pro-rated based on days served in the applicable position.
STOCK COMPENSATION
Annual Full Value Share Grant:
Each Director will receive on the date of the Elevance Health, Inc. annual meeting of shareholders, subject to the deferral described below, an annual grant of a number of shares equal in value to $210,000 (the “Annual Full Value Share Grant”). The exact number of shares for each Annual Full Value Share Grant will be calculated using the following formula:
[$210,000] ÷ [the closing price of the Elevance Health,
Inc. common stock as reported on the New York Stock Exchange on the date of the annual meeting of shareholders] = Number of shares of the Annual Full Value Share Grant.
Partial Value Share Grants:
Any Director who joins the Board of Directors after the date of the Elevance Health, Inc. annual meeting of shareholders (the “Effective Date”) shall receive a pro-rated share grant (the “Partial Value Share Grant”) on the first business day of the month following the Effective Date (unless the Effective Date is on the first business day of a month, in which case, the grant shall be made on the Effective Date). The Partial Value Share Grant shall be subject to the deferral described below. The exact number of shares of the Partial Value Share Grant will be calculated using the following formula:
[$210,000
x (the number of days from the Effective Date to the first annual meeting of shareholders after the Effective Date ÷ 365)] ÷ the closing price of the Elevance Health, Inc. common stock as reported on the New York Stock Exchange on the first business day of the month following the Effective Date (unless the Effective Date is on the first business day of a month, in which case, the closing price on the Effective Date shall be used) = Number of shares of the Partial Value Share Grant.
EXHIBIT 10.7
Deferral of Share Grants:
Share grants will be deferred for a minimum period of five years from the (1) grant date for Annual Full Value Share
Grants and (2) the date of the annual meeting of shareholders that immediately precedes the Effective Date for Partial Value Share Grants (each a “Deferral Period”) in accordance with the terms of the Director Deferred Compensation Plan. Such grants shall not be distributed to the Directors until the earlier of the expiration of the Deferral Period or the date on which a Director ceases to be a member of the Board of Directors.
Director Ownership Guidelines:
Each Director shall have the obligation to own at least $625,000 of Elevance Health, Inc. common stock (including deferred shares and phantom stock, but not options) commencing on the fifth anniversary of the date such Director became a member of the Board of Directors.
MISCELLANEOUS
Annual Physical Exam:
Elevance Health, Inc. will pay the cost of an annual physical examination for each Director.
Expenses:
Elevance Health, Inc. will reimburse each Director for all travel, lodging and other expenses incurred in connection with attendance at and/or participation in any and all Board of Directors and Committee meetings and related matters.
Dates Referenced Herein and Documents Incorporated by Reference